Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART)
Purpose
Treatment options for pancreatic ductal adenocarcinoma (PDAC) are commonly limited for patients with advanced age due to medical comorbidities and/or poor performance status. These patients may not be candidates for more aggressive chemotherapy regimens and/or surgical resection leaving few, if any, other effective treatments. Ablative stereotactic MRI-guided adaptive radiation therapy (A-SMART) is both efficacious and safe for PDAC and can achieve excellent long-term local control, however, the appropriateness of A-SMART for elderly patients with inoperable PDAC is not well understood.
Methods
A retrospective analysis was performed of inoperable non-metastatic PDAC patients aged 75 years or older treated on the MRIdian Linac at 2 institutions. Clinical outcomes of interest included overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional (LRC). Toxicity was graded according to Common Terminology Criteria for Adverse Events (CTCAE, v5).
Results
A total of 49 patients were evaluated with a median age of 81 years (range, 75-91) and a median follow-up of 14 months from diagnosis. PDAC was classified as locally advanced (46.9%), borderline resectable (36.7%), or medically inoperable (16.3%). Neoadjuvant chemotherapy was delivered to 84% of patients and all received A-SMART to a median 50 Gy (range, 40-50 Gy) in 5 fractions. 1 Year LRC, PFS, and OS were 88.9%, 53.8%, and 78.9%, respectively. Nine patients (18%) had resection after A-SMART and benefited from PFS improvement (26 vs 6 months, P = .01). ECOG PS <2 was the only predictor of improved OS on multivariate analysis. Acute and late grade 3 + toxicity rates were 8.2% and 4.1%, respectively.
Conclusions
A-SMART is associated with encouraging LRC and OS in elderly patients with initially inoperable PDAC. This novel non-invasive treatment strategy appears to be well-tolerated in patients with advanced age and should be considered in this population that has limited treatment options.
Top-30
Journals
|
1
|
|
|
Cancers
1 publication, 8.33%
|
|
|
Seminars in Radiation Oncology
1 publication, 8.33%
|
|
|
Clinical and Translational Radiation Oncology
1 publication, 8.33%
|
|
|
Communications Medicine
1 publication, 8.33%
|
|
|
Radiation Oncology
1 publication, 8.33%
|
|
|
Advances in Radiation Oncology
1 publication, 8.33%
|
|
|
Journal of Clinical Medicine
1 publication, 8.33%
|
|
|
Die Onkologie
1 publication, 8.33%
|
|
|
Cancer
1 publication, 8.33%
|
|
|
Journal of Clinical Investigation
1 publication, 8.33%
|
|
|
Translational Gastroenterology and Hepatology
1 publication, 8.33%
|
|
|
AME Clinical Trials Review
1 publication, 8.33%
|
|
|
1
|
Publishers
|
1
2
3
|
|
|
Elsevier
3 publications, 25%
|
|
|
Springer Nature
3 publications, 25%
|
|
|
MDPI
2 publications, 16.67%
|
|
|
AME Publishing Company
2 publications, 16.67%
|
|
|
Wiley
1 publication, 8.33%
|
|
|
American Society for Clinical Investigation
1 publication, 8.33%
|
|
|
1
2
3
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.